>북미 월경통 치료 시장, 유형별(1차성 월경통, 2차성 월경통), 치료 유형(약물, 요법, 수술, 기타), 처방 방식(처방전 없이, 처방), 투여 경로(경구, 비경구, 임플란트, 기타), 최종 사용자(병원, 전문 센터, 외래 수술 센터, 기타), 유통 채널(약국, 소매 판매, 직접 입찰, 기타), 국가(미국, 캐나다, 멕시코) 산업 동향 및 2028년까지의 예측
시장 분석 및 통찰력: 북미 월경통 치료 시장
월경통 치료 시장은 2021년에서 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2021년에서 2028년까지의 예측 기간 동안 7.6%의 CAGR로 성장하고 있으며 2028년까지 3,335.97백만 달러에 도달할 것으로 예상한다고 분석합니다. 월경통과 같은 월경 건강 질환의 유병률 증가와 월경통 치료에 대한 광범위한 연구 개발 활동이 예측 기간 동안 시장 수요를 촉진한 주요 원동력입니다.
월경통은 신체 하복부에 느껴지는 경련과 욱신거리는 통증입니다. 많은 여성들이 월경 전후에 월경통을 겪습니다. 어떤 여성에게는 월경통이 흔한 반면, 다른 여성에게는 월경통이 성가시고 매우 심해서 매달 며칠 동안 일상 생활을 방해합니다. 월경통의 증상은 월경 1~3일 전에 시작되는 통증이며, 월경이 시작된 후 24시간에 최고조에 달하고 2~3일 후에 가라앉으며 둔함, 지속적인 통증, 메스꺼움, 두통, 현기증 , 설사 등이 있습니다.
월경통 치료는 월경통에 대한 효과적인 치료에 대한 필요성이 증가함에 따라 제조업체가 시장에 신제품을 출시하는 데 영향을 미치고, 이는 수요를 증가시키고, 정부와 제약 산업의 이니셔티브가 증가함에 따라 월경통 치료 시장이 성장합니다. 대체 요법의 사용은 월경통 치료 시장 성장에 도전이 됩니다.
현재, 제조업체가 새롭고 혁신적인 기술을 개발할 수 있는 경쟁 우위를 만들어 줄 것으로 기대되는 인식 프로그램이 진행 중입니다. 게다가, 이러한 인식 프로그램은 또한 월경통 치료 시장에서 다양한 다른 기회를 제공할 것으로 기대됩니다. 그러나 전통적인 치료법의 존재는 예측 기간 동안 월경통 치료 시장 성장을 제한할 것으로 예상됩니다.
월경통 치료 시장 보고서는 시장 점유율, 새로운 개발 및 제품 파이프라인 분석, 국내 및 지역 시장 참여자의 영향, 새로운 수익 주머니, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서의 분석 기회에 대한 세부 정보를 제공합니다. 분석 및 월경통 치료 시장 시나리오를 이해하려면 Data ridge Market Research에 연락하여 분석가 브리핑을 요청하세요. 당사 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드립니다.
북미 월경통 치료 시장 범위 및 시장 규모
월경통 치료 시장은 유형, 치료 유형, 처방 방식, 투여 경로, 최종 사용자 및 유통 채널을 기준으로 세분화됩니다. 세그먼트 간의 성장은 틈새 성장 포켓과 시장에 접근하고 핵심 응용 분야와 타겟 시장의 차이점을 파악하기 위한 전략을 분석하는 데 도움이 됩니다.
- 유형에 따라 월경통 치료 시장은 원발성 월경통과 이차성 월경통으로 구분됩니다. 2021년에는 원발성 월경통 세그먼트가 월경통 치료 시장을 지배하고 있으며, 미국 여성의 85%가 월경 중 월경통을 겪거나 겪고 있습니다.
- 치료 유형에 따라 월경통 치료 시장은 약물 , 요법, 수술 및 기타로 세분화됩니다. 2021년에는 약물 부문이 월경통 치료 시장을 지배하고 있는데, 이는 약물 비스테로이드성 항염제와 복합 경구 피임약이 월경통에 대한 1차 치료법이기 때문입니다.
- 처방 방식에 따라 월경통 치료 시장은 처방 과 일반 의약품으로 세분화됩니다. 2021년에는 일반 의약품 부문이 월경통 치료 시장을 지배하고 있는데, 대부분의 약물이 제네릭으로 제공되고 제약 제품을 아무런 방해 없이 공급하며 광고의 미덕으로 대중에게 인지도를 높이기 때문입니다.
- 투여 경로에 따라 월경통 치료 시장은 경구, 비경구 , 임플란트 및 기타로 세분화됩니다. 2021년에는 경구 세그먼트가 월경통 치료 시장을 지배하고 있는데, 경구 세그먼트가 첫 번째 치료 라인으로 간주되기 때문입니다. 더욱이 경구 약물은 환자의 준수도가 더 좋으며, 이는 또 다른 추진 요인으로 작용합니다.
- 최종 사용자를 기준으로 월경통 치료 시장은 병원 , 외래 수술 센터, 전문 센터 등으로 세분화됩니다. 2021년에는 병원 부문이 월경통 치료 시장을 지배하고 있는데, 대부분 환자가 폐경 증상을 겪고 있어 적절한 진단과 치료를 받기 위해 병원에 가야 하기 때문입니다.
- 유통 채널을 기준으로 월경통 치료 시장은 직접 입찰, 소매 판매, 약국 및 기타로 세분화됩니다. 2021년에는 약국 부문이 월경통 치료 시장을 지배하고 있으며, 환자의 필요와 수요에 따라 다양한 의약품이 약국에서 판매되고 있습니다.
월경통 치료 시장 국가 수준 분석
위에 언급된 대로, 국가, 유형, 치료 유형, 처방 방식, 투여 경로, 최종 사용자 및 유통 채널별로 생리통 치료 시장을 분석하고 시장 규모 정보를 제공합니다.
북미 생리통 치료 시장 보고서에서 다루는 국가는 미국, 캐나다, 멕시코입니다.
북미의 처방 모드 세그먼트는 이 지역 환자들의 OTC 월경통 치료제 채택률이 높아 시장을 지배할 것으로 예상됩니다 . 미국은 이 지역에서 주요 시장 참여자들의 존재감이 커져 북미 시장을 지배하고 성장을 이끌고 있습니다.
보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 북미 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
월경통 치료 시장에서 치료 옵션의 증가는 시장 참여자들에게 새로운 기회를 창출하고 있습니다.
월경통 치료 시장은 또한 월경통 치료 판매와 함께 미용 산업의 모든 국가적 성장에 대한 자세한 시장 분석, 월경통 치료 발전의 영향, 월경통 치료 시장에 대한 지원과 함께 규제 시나리오의 변화를 제공합니다. 이 데이터는 2010년부터 2019년까지의 과거 기간에 대해 제공됩니다.
경쟁 환경 및 월경통 치료 시장 점유율 분석
월경통 치료 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보에는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭과 폭, 응용 분야 우세, 기술 생명선 곡선이 있습니다. 제공된 위의 데이터 포인트는 월경통 치료 시장과 관련된 회사의 초점에만 관련이 있습니다.
월경통 치료를 취급하는 주요 기업으로는 Bayer AG, GlaxoSmithKline plc, Pfizer Inc., Teva Pharmaceuticals USA, Inc.(Teva Pharmaceutical Industries Ltd.의 자회사), Beurer GmbH, Mylan NV(Viatris Inc.의 일부), Boehringer Ingelheim International GmbH, PMS4PMS, LLC, Sanofi, Nobelpharma Co., Ltd., ObsEva, Myovant Sciences Ltd., AbbVie Inc., BioElectronics Corporation, Alvogen, Cumberland Pharmaceuticals Inc., Lupin Pharmaceuticals, Inc.(LUPIN의 자회사), Janssen Pharmaceuticals, Inc.(Johnson & Johnson Services, Inc.의 자회사), Sun Pharmaceutical Industries Ltd. 등이 있습니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁사에 대한 경쟁 분석을 별도로 제공합니다.
또한 전 세계 여러 회사에서 많은 제품 출시와 계약을 체결하면서 생리통 치료 시장도 활성화되고 있습니다.
예를 들어,
- 2019년 5월, PMS4PMS, LLC는 Comforte라는 제품 출시를 발표했습니다. 이 제품은 월경 주기 동안 생리통을 완화해줍니다. 이 회사가 출시한 이 신제품은 시장에서 수요와 판매를 증가시켰습니다.
시장 참여자들의 협력, 합작투자 및 기타 전략은 월경통 치료 시장에서 회사 시장을 확대하고 있으며, 이를 통해 기업들은 월경통 치료에 대한 제공 서비스를 개선하는 데에도 도움이 됩니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PIPELINE ANALYSIS
4.1 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, PIPELINE ANALYSIS
5 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: REGULATIONS
6 PREMIUM INSIGHTS
6.1 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: ADOPTION RATE
6.1.1 DRIVERS AND BARRIERS FOR THE ADOPTIONS
6.2 MARKETING EXPENSES
6.3 PAYERS:
6.4 PHARMACIES COLD/HOT PADS MARKET SHARE:
7 EPIDEMIOLOGY
8 COVID-19 IMPACT ON NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET
8.1 PRICE IMPACT
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC INITIATIVES BY MARKET PLAYERS DURING COVID-19
8.5 CONCLUSION
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 GROWING PREVALENCE OF DYSMENORRHEA
9.1.2 RISING TECHNOLOGICAL ADVANCEMENTS
9.1.3 INCREASING RESEARCH AND DEVELOPMENT FOR DEVELOPING INNOVATIVE DRUGS AND THERAPIES
9.1.4 GOVERNMENT INITIATIVES WITH RESPECT TO WOMEN HEALTHCARE
9.1.5 INCREASING NUMBER OF TREATMENT OPTIONS
9.2 RESTRAINTS
9.2.1 PRODUCT RECALLS
9.2.2 LACK OF AWARENESS ABOUT REPRODUCTIVE HEALTH IN WOMEN
9.2.3 HIGH COST OF ENDOMETRIAL ABLATION AND HYSTERECTOMY
9.3 OPPORTUNITIES
9.3.1 RISE IN AWARENESS ABOUT DYSMENORRHEA
9.3.2 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS
9.3.3 RISING DISPOSABLE INCOME
9.4 CHALLENGES
9.4.1 TRADITIONAL FAMILY VALUE LEADING TO NO TREATMENT
9.4.2 SIDE EFFECTS AND COMPLICATIONS ASSOCIATED WITH LONG TERM TREATMENT
9.4.3 EFFECTIVENESS OF COMPLEMENTARY AND ALTERNATIVE THERAPIES
10 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE
10.1 OVERVIEW
10.2 PRIMARY DYSMENORRHEA
10.3 SECONDARY DYSMENORRHEA
11 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE
11.1 OVERVIEW
11.2 MEDICATION
11.2.1 FIRST LINE TREATMENT
11.2.1.1 Nonhormonal Therapy
11.2.1.1.1 Nonsteroidal Anti-Inflammatory Drugs
11.2.1.1.1.1 Ibuprofen
11.2.1.1.1.2 Naproxen
11.2.1.1.1.3 Celecoxib
11.2.1.1.1.4 Mefenamic Acid
11.2.1.1.1.5 Meclofenamate
11.2.1.1.2 Acetaminophen
11.2.1.2 Hormonal Replacement Therapy y
11.2.1.2.1 Combined Oral Contraceptives (Monophasic or Multiphasic)
11.2.1.2.1.1 Norethindrone/Ethinyl Estradiol
11.2.1.2.1.2 Extended-Cycle Oral Contraceptives
11.2.1.2.2 Extended-Cycle Oral Contraceptives
11.2.1.2.2.1 Levonorgestrel/Ethinyl Estradiol
11.2.1.2.2.2 Others
11.2.1.2.3 Other
11.2.1.2.3.1 Etonogestrel/Ethinyl Estradiol
11.2.1.2.3.2 Etonogestrel Implant
11.2.1.2.3.3 Levonorgestrel-Releasing Intrauterine System
11.2.1.2.3.4 Medroxyprogesterone Shot
11.2.1.3 Diuretic
11.2.1.3.1 Spironolactone
11.2.1.3.2 Ammonium Chloride
11.2.1.4 Antidepressants
11.2.2 SECOND LINE TREATMENT
11.2.2.1 Empiric GNRH Analogue or Antagonist Therapy
11.2.2.2 Ammonium Chloride
11.3 THERAPY
11.3.1 HEAT THERAPY
11.3.1.1 Patch
11.3.1.2 Wrap
11.3.1.3 Ceramic Belt Emitting Far-Infrared Radiation (FIR)
11.3.2 BEHAVIORAL COUNSELING
11.3.2.1 Desensitization-Based Procedures
11.3.2.2 Coping Strategies
11.3.2.3 Imagery
11.3.2.4 Hypnotherapy
11.3.2.5 Others
11.3.3 DIET AND VITAMINS
11.3.3.1 Vitamin E
11.3.3.2 Vitamin B
11.3.3.3 Vitamin D
11.3.3.4 Others
11.4 SURGERY
11.4.1 ENDOMETRIAL ABLATION
11.4.2 HYSTERECTOMY
11.5 OTHERS
12 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION
12.1 OVERVIEW
12.2 OVER THE COUNTER
12.3 PRESCRIPTION
13 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
13.1 OVERVIEW
13.2 ORAL
13.2.1 TABLETS
13.2.2 PILLS
13.2.3 CAPSULE
13.2.4 OTHERS
13.3 PARENTERAL
13.3.1 INTRAVENOUS
13.3.2 SUBCUTANEOUS
13.3.3 OTHERS
13.4 IMPLANTS
13.5 OTHERS
14 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALTY CENTERS
14.4 AMBULATORY SURGICAL CENTERS
14.5 OTHERS
15 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 PHARMACIES
15.2.1 HOSPITAL
15.2.2 RETAIL
15.3 DIRECT TENDER
15.4 RETAIL SALES
15.5 OTHERS
16 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY GEOGRAPHY
16.1 NORTH AMERICA
16.1.1 U.S
16.1.2 CANADA
16.1.3 MEXICO
17 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 GLAXOSMITHKLINE PLC.
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 JANSSEN PHARMACEUTICALS, INC. (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENT
19.3 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANLYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENTS
19.4 ABBVIE INC.
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 MYLAN N. V. (A PART OF VIATRIS INC.).
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 PRODUCT PORTFOLIO
19.5.4 RECENT DEVELOPMENT
19.6 ALVOGEN
19.6.1 COMPANY SNAPSHOT
19.6.2 PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENT
19.7 BAYER AG
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENTS
19.8 BEURER GMBH
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENT
19.9 BIOELECTRONICS CORPORATION
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENT
19.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENT
19.11 COLOR SEVEN CO., LTD.
19.11.1 COMPANY SNAPSHOT
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENTS
19.12 CUMBERLAND PHARMACEUTICALS INC.
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 LIVIA
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENTS
19.14 LUPIN PHARMACEUTICALS, INC. (A SUBSIDIARY OF LUPIN)
19.14.1 COMPANY SNAPSHOT
19.14.2 REVENUE ANALYSIS
19.14.3 PRODUCT PORTFOLIO
19.14.4 RECENT DEVELOPMENTS
19.15 MYOVANT SCIENCES LTD.
19.15.1 COMPANY SNAPSHOT
19.15.2 PRODUCT PORTFOLIO
19.15.3 RECENT DEVELOPMENT
19.16 NOBELPHARMA CO., LTD.
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENT
19.17 OBSEVA
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORTFOLIO
19.17.3 RECENT DEVELOPMENTS
19.18 PFIZER INC.
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENTS
19.19 PMS4PMS, LLC
19.19.1 COMPANY SNAPSHOT
19.19.2 PRODUCT PORTFOLIO
19.19.3 RECENT DEVELOPMENT
19.2 SANOFI
19.20.1 COMPANY SNAPSHOT
19.20.2 REVENUE ANALYSIS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENT
19.21 SUN PHARMACEUTICAL INDUSTRIES LTD.
19.21.1 COMPANY SNAPSHOT
19.21.2 REVENUE ANALYSIS
19.21.3 PRODUCT PORTFOLIO
19.21.4 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
표 목록
LIST OF TABLES
TABLE 1 MARKETING EXPENSES OF THE MARKET PLAYERS
TABLE 2 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 3 NORTH AMERICA PRIMARY DYSMENORRHEA IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 NORTH AMERICA SECONDARY DYSMENORRHEA IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 6 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 7 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 8 NORTH AMERICA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 NORTH AMERICA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 21 NORTH AMERICA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 22 NORTH AMERICA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA OVER THE COUNTER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 NORTH AMERICA PRESCRIPTION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 31 NORTH AMERICA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 NORTH AMERICA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 33 NORTH AMERICA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 NORTH AMERICA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 35 NORTH AMERICA IMPLANTS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 NORTH AMERICA OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY END USER, 2020-2028 (USD MILLION)
TABLE 38 NORTH AMERICA HOSPITALS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 NORTH AMERICA SPECIALTY CENTERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 NORTH AMERICA OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 42 NORTH AMERICA CANCER SUPPORTIVE CARE PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
TABLE 43 NORTH AMERICA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 NORTH AMERICA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 45 NORTH AMERICA DIRECT TENDER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 46 NORTH AMERICA RETAIL SALES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 NORTH AMERICA OTHERS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 48 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 49 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 50 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 51 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 52 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 53 NORTH AMERICA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 54 NORTH AMERICA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 55 NORTH AMERICA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 56 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 57 NORTH AMERICA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 58 NORTH AMERICA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 59 NORTH AMERICA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 60 NORTH AMERICA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 61 NORTH AMERICA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 62 NORTH AMERICA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 63 NORTH AMERICA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 64 NORTH AMERICA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 65 NORTH AMERICA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 66 NORTH AMERICA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 67 NORTH AMERICA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 68 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 69 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 70 NORTH AMERICA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 71 NORTH AMERICA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 72 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 73 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 74 NORTH AMERICA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 75 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 77 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 78 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 79 U.S. MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 80 U.S. FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 81 U.S. NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 82 U.S. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 83 U.S. HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 84 U.S. COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 85 U.S. EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 86 U.S. OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 87 U.S. DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 88 U.S. SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 89 U.S. THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 90 U.S. HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 91 U.S. BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 92 U.S. DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 93 U.S. SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 94 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 95 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 96 U.S. ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 97 U.S. PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 98 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 99 U.S. MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 100 U.S. PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 101 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 102 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 103 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 104 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 105 CANADA MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 106 CANADA FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 107 CANADA NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 108 CANADA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 109 CANADA HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 110 CANADA COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 111 CANADA EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 112 CANADA OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 113 CANADA DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 114 CANADA SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 115 CANADA THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 116 CANADA HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 117 CANADA BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 118 CANADA DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 119 CANADA SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 120 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 121 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 122 CANADA ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 123 CANADA PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 124 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 125 CANADA MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 126 CANADA PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 127 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 128 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 129 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (UNITS)
TABLE 130 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (ASP)
TABLE 131 MEXICO MEDICATION IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 132 MEXICO FIRST LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 133 MEXICO NONHORMONAL THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 134 MEXICO NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 135 MEXICO HORMONAL REPLACEMENT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 136 MEXICO COMBINED ORAL CONTRACEPTIVES (MONOPHASIC OR MULTIPHASIC) IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 137 MEXICO EXTENDED-CYCLE ORAL CONTRACEPTIVES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 138 MEXICO OTHER IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 139 MEXICO DIURETIC IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 140 MEXICO SECOND LINE TREATMENT IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 141 MEXICO THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 142 MEXICO HEAT THERAPY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 143 MEXICO BEHAVIORAL COUNSELING IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 144 MEXICO DIET AND VITAMINS IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 145 MEXICO SURGERY IN MENSTRUAL CRAMPS TREATMENT MARKET, BY TREATMENT TYPE, 2019-2028 (USD MILLION)
TABLE 146 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY MODE OF PRESCRIPTION, 2019-2028 (USD MILLION)
TABLE 147 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 148 MEXICO ORAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 149 MEXICO PARENTERAL IN MENSTRUAL CRAMPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 150 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 151 MEXICO MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 152 MEXICO PHARMACIES IN MENSTRUAL CRAMPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
그림 목록
LIST OF FIGURES
FIGURE 1 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 10 INCREASING PREVALENCE OF DYSMENORRHEA IS EXPECTED TO DRIVE THE NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 11 PRIMARY DYSMENORRHEA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET IN 2021 & 2028
FIGURE 12 PHARMACIES COLD/HOT PADS MARKET SHARE: 2020 (%)
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET
FIGURE 14 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, 2020
FIGURE 15 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 16 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 17 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, 2020
FIGURE 19 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, 2020-2028 (USD MILLION)
FIGURE 20 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2021-2028)
FIGURE 21 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 22 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, 2020
FIGURE 23 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION 2020-2028 (USD MILLION)
FIGURE 24 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, CAGR (2021-2028)
FIGURE 25 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY MODE OF PRESCRIPTION, LIFELINE CURVE
FIGURE 26 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 27 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 28 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 29 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 30 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, 2020
FIGURE 31 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 32 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, CAGR (2021-2028)
FIGURE 33 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 35 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 36 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 37 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: SNAPSHOT (2020)
FIGURE 39 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2020)
FIGURE 40 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2021 & 2028)
FIGURE 41 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY COUNTRY (2020 & 2028)
FIGURE 42 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: BY TYPE (2021-2028)
FIGURE 43 NORTH AMERICA MENSTRUAL CRAMPS TREATMENT MARKET: COMPANY SHARE 2020 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
